Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study

Table 1 Baseline characteristics of patients with autoimmune hepatitis and non-chronic liver diseases patients with a positive test for severe acute respiratory syndrome coronavirus-2

Variables	Before propensity score matching			After propensity score matching
	AIH (n = 375)	Non-CLD (n = 1647915)	P value	AIH (n = 375)	Non-CLD (n = 375)	P value
Age, yr, mean ± SD	53.1 ± 18.4	46.4 ± 18.8	< 0.01	53.1 ± 8.4	53.2 ± 8.2	0.97
Sex, n (%)
Female	271 (72.2)	893768 (54.2)	< 0.01	271 (72.2)	256 (68.2)	0.23
Ethnicity, n (%)
Hispanic or Latino	37 (9.8)	144535 (8.7)	0.45	37 (9.8)	36 (9.6)	0.90
Race, n (%)
White	238 (63.4)	1028824 (62.4)	0.68	238 (63.4)	228 (60.8)	0.45
Black or African American	64 (17.1)	245820 (14.9)	0.24	64 (17.1)	69 (18.4)	0.63
Other	65 (17.3)	325638 (19.7)	0.24	65 (17.3)	69 (18.4)	0.70
Nicotine dependence, n (%)	76 (20.2)	181270 (10.9)	< 0.01	72 (19.2)	74 (19.7)	0.67
BMI (kg/m2), mean ± SD	28.9 ± 7.05	29.9 ± 7.45	0.07	28.9 ± 7.05	30.8 ± 7.65	0.01
Comorbidities, n (%)
Hypertension	163 (43.4)	384968 (23.3)	< 0.01	163 (43.4)	159 (42.4)	0.77
Ischemic heart diseases	59 (15.7)	119162 (7.2)	< 0.01	59 (15.7)	57 (15.2)	0.84
Heart failure	38 (10.1)	65245 (3.9)	< 0.01	38 (10.1)	37 (9.8)	0.90
Diabetes	74 (19.7)	171727 (10.4)	< 0.01	74 (19.7)	68 (18.1)	0.58
Chronic lower respiratory diseases	82 (21.8)	235406 (14.2)	< 0.01	82 (21.8)	81 (21.6)	0.93
Cerebrovascular diseases	37 (9.8)	73209 (4.4)	< 0.01	37 (9.8)	39 (10.4)	0.81
CKD of any stage	46 (12.2)	78265 (4.7)	< 0.01	46 (12.2)	37 (9.8)	0.29
Neoplasms	125 (33.3)	293362 (17.8)	< 0.01	125 (33.3)	132 (35.2)	0.59

AIH: Autoimmune hepatitis; CLD: Chronic liver diseases; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; SD: Standard deviation; BMI: Body mass index; CKD: Chronic kidney disease.